AGN 195263

Drug Profile

AGN 195263

Alternative Names: AGN-195263

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Allergan
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry eyes
  • Phase II Meibomianitis

Most Recent Events

  • 28 Jun 2017 Allergan terminates a phase III trial for Dry eyes in USA (Ophthalmic) (NCT02815293)
  • 01 Dec 2016 Allergan initiates enrolment in a phase III trial for Dry eyes in USA (NCT02965846)
  • 16 Nov 2016 Allergan plans a phase III trial for Dry eyes in USA, Czech Republic, France, Germany, Hungary, Italy, Philippines, Poland, Spain, Taiwan, Turkey and United Kingdom (Opthalmic) (NCT02965846)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top